|
Patent landscape, scope, and claims: |
Scope and claims of US Patent 7,563,801: crystalline hydrochloride monohydrate formulation, XRD fingerprint, dissolution, PK, and capsule granulation process
US Patent 7,563,801 is a formulation-and-physicochemical identity patent built around one specific active pharmaceutical ingredient (API) form: a crystalline hydrochloride monohydrate salt of a defined diazaspiro compound (the salt of the (5S,8S) substituted diazaspiro[4.5]decan-2-one bearing a 1-(3,5-bis-(trifluoromethyl)phenyl)ethoxy substituent). Claim scope is concentrated in four claim clusters: (i) composition (API form + excipient package), (ii) API identity via X-ray powder diffraction (XRD) peaks, (iii) performance via dissolution and PK, and (iv) manufacturing/process features (granulation and milling/drying steps) plus downstream capsule embodiments and dose-specific dissolution windows.
High-level takeaway on claim scope
- The patent reads on capsules and granulate-based solid dosage forms that contain the claimed crystalline hydrochloride monohydrate plus a defined excipient system.
- It also reads on granulate prepared by a specific wet granulation route (water amount constraint via “< about 32 wt.% water,” wet milling through an 8 to 10 mesh sieve, fluid-bed drying) and then blended with a specified secondary excipient blend.
- It restricts the protected API identity through XRD “characteristic peaks” at specific 2θ values (±0.2° tolerance) with specified qualitative relative intensities.
What the patent is not covering (based on the provided claim text)
- It is not framed as a broad “any salt” or “any polymorph” claim. It is narrowed to a particular crystalline hydrochloride monohydrate with a specific XRD peak set, and to formulations with the listed excipients and capsule/granulate delivery form.
- It does not appear (from the claim set provided) to protect broad combination regimens unless the combination is expressed as “the formulation… and other therapeutic agents,” plus a dependent claim where the additional therapeutic agent is temozolomide.
What exactly does US 7,563,801 claim: composition scope of the hydrochloride monohydrate plus excipients
Independent claim 1 defines the core protected subject matter as a pharmaceutical formulation comprising:
- Crystalline hydrochloride monohydrate of the specific diazaspiro compound
- Lactose
- Microcrystalline cellulose
- Croscarmellose sodium
- Pregelatinized starch
- Magnesium stearate
Key composition elements and practical claim boundaries
-
API identity anchor
- The API is not merely “the compound,” but specifically “crystalline hydrochloride monohydrate salt” of the defined structure.
- This is the principal gatekeeper for infringement. If a competitor uses a different salt form (e.g., free base, different hydrate, different counterion) or a different crystalline form that fails the XRD fingerprint, claim coverage becomes difficult.
-
Excipient package
- Claim 1 lists a classic oral solid formulation toolkit: lactose + MCC + croscarmellose sodium + pregelatinized starch + magnesium stearate.
- Dependent claim 8 narrows lactose to lactose monohydrate.
-
Delivery form not explicit in claim 1
- Capsules appear in multiple dependent claims (claims 5–7 and 12–14), indicating the practical commercial embodiment is capsule dosage.
Claim strength implication
- For generic or reformulation risk assessment, API crystal form and the excipient set are the main infringement levers. If the excipients match but the API form differs, XRD-dependent claims may be avoided. If the API form matches but the excipient package differs, claim 1 can be avoided unless the doctrine of equivalents is asserted in litigation.
Does US 7,563,801 require a specific X-ray diffraction pattern to infringe
Yes. Claims 3, 4, 11 expressly require an X-ray powder diffraction pattern with specified characteristic peaks.
XRD feature set (characteristic peaks)
Provided characteristic peaks and tolerances:
- 2θ = 16.1° (±0.2°), RI: Medium, d = 5.49 Å (±0.04)
- 2θ = 18.4° (±0.2°), RI: Medium, d = 4.83 Å (±0.04)
- 2θ = 21.6° (±0.2°), RI: Strong, d = 4.11 Å (±0.04)
- 2θ = 23.5° (±0.2°), RI: Weak, d = 3.78 Å (±0.04)
How these dependent claims work
- Claim 3: formulation of claim 1 where the hydrochloride monohydrate salt has this XRD pattern.
- Claim 4: formulation of claim 2 with the same XRD requirement (PK-linked claim + XRD).
- Claim 11: formulation of claim 10 with the same XRD requirement.
Infringement risk design space for competitors
- A manufacturer attempting to avoid these claims would need to show the marketed API’s XRD does not match the listed characteristic peaks under the stated measurement conditions/tolerances.
- Conversely, a generic development effort that replicates the same crystal form will likely land inside the XRD envelope, triggering these dependent claim pathways.
Practical litigation lever
- XRD claims are often litigated via expert powder XRD comparisons. Here, the patent provides explicit 2θ values, RI qualitative categories, and d-spacing, plus tolerances. That increases evidentiary utility versus purely descriptive polymorph language.
What PK data is protected: does US 7,563,801 cover performance beyond identity
Claim 2 and 15 add PK profile limitations tied to dosing and measurable plasma parameters:
- Cmax (ng/mL), Tmax (hours), AUC (0–72h), and T½ (hours)
- Doses: 5, 10, 25, 50, 100, 200 mg
PK table from claim 2 (and claim 15 repeats it)
Dose and parameters:
- 5 mg: Cmax 27.3 ng/mL, Tmax 2 h, AUC 931, T½ not calc.
- 10 mg: Cmax 52.7 ng/mL, Tmax 2.5 h, AUC 1820, T½ not calc.
- 25 mg: Cmax 119 ng/mL, Tmax 2.5 h, AUC 17,200, T½ 183 h
- 50 mg: Cmax 276 ng/mL, Tmax 3 h, AUC 33,600, T½ 171 h
- 100 mg: Cmax 475 ng/mL, Tmax 2 h, AUC 74,400, T½ 181 h
- 200 mg: Cmax 944 ng/mL, Tmax 4 h, AUC 148,000, T½ 169 h
Does this expand or narrow coverage
- It narrows coverage because the protected subject matter is not only the formulation composition and crystal form, but the formulation that provides the stated PK behavior at the dosing regimens.
- In practice, the PK limitation can become a contested issue: if a generic matches the formulation and crystal form, PK likely matches or can be argued as “same product” pharmacokinetics. If formulation processing changes (particle size distribution, capsule fill weight, dissolution rate, water content, etc.), PK can shift.
Portfolio consequence
- The patent has a multi-axis strategy: it tries to make identity provable (XRD), performance provable (dissolution + PK), and manufacturing reproducible (granulation process).
What dissolution profiles does US 7,563,801 protect for each capsule dose
Capsule claims 5–7 (and corresponding 12–14 for XRD-conditioned claim sets) embed dissolution windows in specific media using USP apparatus specifications.
Dissolution medium and apparatus (common)
- 900 mL
- Dissolution medium: 0.25% sodium lauryl sulfate solution buffered with 0.05 M sodium acetate at pH 4.5
- USP Apparatus 2 (paddle), sometimes paddle with sinkers at 75 RPM
- Time points: 5, 15, 30, 45, 60 minutes (dose dependent tables)
Dose-specific dissolution windows
Claim 5: 2.5 mg dose (USP 2 Paddle)
- 5 min: 69% (range 64%–74%)
- 15 min: 88% (range 83%–94%)
- 30 min: 94% (range 90%–100%)
- 45 min: 97% (range 93%–102%)
- 60 min: 98% (range 94%–103%)
Claim 6: 10 mg dose (USP 2 Paddle Stirrer with sinkers, 75 RPM)
- 5 min: 87% (range 82%–91%)
- 15 min: 95% (range 91%–98%)
- 30 min: 98% (range 94%–100%)
- 45 min: 98% (range 95%–101%)
- 60 min: 99% (range 96%–100%)
Claim 7: 50 mg dose (USP 2 Paddle Stirrer with sinkers, 75 RPM)
- 5 min: 88% (range 74%–96%)
(wider early window)
- 15 min: 97% (range 91%–101%)
- 30 min: 99% (range 94%–102%)
- 45 min: 100% (range 95%–102%)
- 60 min: 100% (range 96%–103%)
The XRD-conditioned dissolution claims
- Claims 12–14 replicate the same dissolution profiles but are tied to formulation of claim 11, which includes the XRD requirement.
Infringement implication
- Even if a competitor matches the excipient composition and uses capsules, failure to match the crystalline API XRD may avoid claims with XRD conditions.
- Conversely, matching the API crystal form and manufacturing approach likely forces dissolution performance into the protected window, especially if wet granulation parameters are replicated.
How does the capsule and granulation process claim change the patent landscape
Claim 10 is a process-backed formulation claim. It protects a formulation prepared by a process that includes:
-
Dry blending:
- crystalline hydrochloride monohydrate salt of Formula I
- lactose monohydrate
- croscarmellose sodium
- pregelatinized starch
to form a homogeneous powder blend
-
Granulating with purified water until the granulate has less than about 32 wt.% water
-
Wet milling:
- through an 8 to 10 mesh screen sieve
-
Drying:
-
Blending:
- the granulate with
- microcrystalline cellulose
- croscarmellose sodium
- magnesium stearate
to form a homogeneous powdered formulation
What this adds versus claim 1
- It adds a manufacturing pathway limitation. A competitor making the same final capsule formulation could attempt to reduce process-based infringement risk by using different unit operations or different water content targets, milling screen size, or drying modality.
- But because this is a formulation claim “prepared by the process,” litigation can still treat the final product as evidence of process equivalence depending on proof burdens.
Process-to-performance link
The same patent ties the claimed process to the resulting dissolution behavior and PK. That increases the patent’s internal consistency: process controls are used to engineer particle properties, which then drive dissolution.
Does US 7,563,801 protect capsule granulate quality via tablet-like Q-45
Claim 9: capsule filled with granulate prepared in accordance with claim 1, characterized by Q-45 not less than 75% under S-1 conditions when tested as a six tablet average.
- This reads as a flow/handling or dissolution-related quality parameter depending on the “Q-45” test definition used in the patent’s technical standard.
- Operationally, it creates another barrier to design-around: even if composition and crystal form match, granulate quality metrics may differ if the manufacturing route is changed.
Is temozolomide or combination therapy covered under US 7,563,801
Yes, but coverage is broad in language and depends on claim construction.
- Claim 16: formulation of claim 1 further comprising a chemotherapeutic agent.
- Claim 17: the chemotherapeutic agent is temozolomide.
- Claim 18: “combination of the formulation of claim 1 and other therapeutic agents.”
Practical scope consequence
- These are combination claims, not monotherapy-only claims.
- If a competitor sells the formulation together with a specified chemotherapeutic regimen (including temozolomide), there is potential infringement even if the API formulation is otherwise the same.
- The combination claim language does not specify dosing timing (concomitant vs sequential). Claim construction would likely hinge on whether “further comprising” requires a fixed combination in one product or includes co-packaged/co-administered regimens. The exact legal interpretation depends on the patent’s full specification, not provided in the prompt.
How to read the overall claim set: a layered fence around one crystalline salt in one dosage system
US 7,563,801 operates as a layered IP fence:
Layer 1: Chemical identity
- “crystalline hydrochloride monohydrate salt of Formula I” (Claim 1 baseline)
Layer 2: Solid-state fingerprint
- XRD characteristic peaks with specified tolerances and RI categories (Claims 3, 4, 11)
Layer 3: Formulation composition and excipients
- Defined excipient package (Claim 1)
- lactose specifically lactose monohydrate (Claim 8)
Layer 4: Dosage form and performance
- capsule dose-specific dissolution windows (Claims 5–7; 12–14)
- PK exposure profile tied to dose (Claims 2; 15)
Layer 5: Manufacturing route
- dry blending, wet granulation with water content target, wet milling through 8–10 mesh, fluid bed drying, then blending with specific excipients (Claim 10)
Layer 6: Product-quality parameter
- Q-45 ≥ 75% under S-1 testing (Claim 9)
Layer 7: Combination therapy expansion
- chemotherapeutic agent, including temozolomide (Claims 16–17) and broader other therapeutic agents (Claim 18)
Design-around and infringement pathways: what a generic or reformulation effort would target
Based strictly on the claim text, the highest-leverage design-around variables are:
-
API salt form / polymorph / hydrate form
- If not the same “crystalline hydrochloride monohydrate,” claim 1 may fail.
- If the salt is “monohydrate” but has different XRD peaks, XRD-dependent claims (3,4,11 and dissolution versions tied to them) can potentially be avoided.
-
Excipients
- Claim 1 requires a specific excipient set. Substituting lactose form (anhydrous lactose, different binder system) or replacing MCC/croscarmellose/pregelatinized starch with equivalents can be an avoidance route.
- Claim 8 specifically limits lactose to lactose monohydrate in the lactose-dependent branch.
-
Process steps
- Claim 10’s unit operations provide a route to avoid process-committed claim scope by using different granulation endpoints, different milling screen sizes, or different drying equipment/parameters.
- Litigation can still infer process similarity from product attributes, but the claim text adds procedural gates.
-
Dissolution and PK performance
- Even if composition and identity are matched, slight formulation or particle property changes can shift dissolution profiles. The patent provides ranges, creating litigation windows rather than point targets.
- A competitor may attempt to target dissolution data outside the claimed ranges in the specific medium and apparatus.
-
Combination therapy
- If sold with temozolomide or other chemotherapeutics, combination claims become relevant. Separate labeling, packaging, or product strategy may matter in how “further comprising” and “combination” are construed.
Key gaps for a full US patent landscape build (and why no landscape tables are included here)
No verifiable bibliographic or legal-status metadata (file history, assignees, continuation/divisional relationships, expiration, terminal disclaimer, prosecution timeline, reexamination, or list of related patents/Family members) is included in the prompt. Without those, a complete “US patent landscape” with expiration/ATD/Orange Book links, inter-family comparisons, and litigation mapping cannot be produced from the claim text alone.
Accordingly, the analysis below stays strictly within the claim scope and practical boundaries shown.
Key Takeaways
- US 7,563,801 protects a specific crystalline hydrochloride monohydrate solid-state form of a defined diazaspiro API, embedded in a capsule formulation with a defined excipient set.
- The patent has a strong identity barrier via XRD characteristic peaks at 16.1°, 18.4°, 21.6°, and 23.5° (±0.2°) with specified qualitative relative intensities and d-spacings.
- It layers protection with dose-specific dissolution windows in 0.25% SLS / 0.05 M sodium acetate pH 4.5 using USP apparatus 2, plus PK exposure constraints (dose-linked Cmax/Tmax/AUC/T½).
- It adds process-committed coverage through a specific wet granulation → wet milling (8–10 mesh) → fluid bed drying route with a water-content endpoint and downstream excipient blending.
- It extends into combination therapy territory, including a dependent claim for temozolomide.
FAQs
-
Can a generic avoid infringement by using a different hydrochloride hydrate or polymorph?
Avoidance is most plausible for claims requiring the specific XRD peak set (Claims 3, 4, 11) if the marketed API fails those diffraction characteristics.
-
Does matching dissolution in water-based media outside pH 4.5 eliminate risk?
Risk remains because the patent defines specific dissolution medium composition and pH plus USP apparatus settings; matching other media may not matter for the claimed dissolution limitations.
-
If a competitor uses the same formulation but a different granulation or milling method, does it still infringe?
For claims tied to the process “prepared by” pathway (Claim 10), using different unit operations can be a design-around route, depending on product proof and claim construction.
-
Are Q-45 and “S-1 conditions” critical to infringement?
Only for the dependent embodiment in Claim 9. Claims 1/3/5/6/7/10/11/12/13/14 can still be asserted without Q-45, but Claim 9 requires meeting that test-defined attribute.
-
Does Claim 18 require co-administration with the other therapeutic agent in a single product?
The provided claim text is broad. Whether it requires a fixed combination, co-packaged dosing, or co-administration is a claim-construction question anchored to the specification and prosecution record, not provided here.
More… ↓
⤷ Start Trial
|
